Literature DB >> 28260356

[Focus on popular science education of glaucoma and reduce glaucomatous low vision and blindness].

X H Sun1.   

Abstract

The prevention of blindness caused by glaucoma is a difficult task. In order to accomplish the task better, we need the participation of whole society and popularize relevant medical knowledge. Popular science and related knowledge of glaucoma are needed to the people especially for high risk population. If people know glaucoma better and actively join the screening of glaucoma, we can find and diagnose glaucoma earlier, avoid late treatment and reduce the glaucomatous visual function impairment. For patients who had been diagnosed with glaucoma, they should aware and accept new medical concept and technique through systemic popular science education. They should actively participate the whole procedure of the disease management and improve their compliance and confidence. Academic organization of ophthalmology should participate and guide the patient education, improve the individualized comprehensive health care for the diagnosis and treatment and third-order health care system that is suitable for the condition of our country, help improving the prognosis of glaucoma and life quality related to vision for advanced and late glaucoma. (Chin J Ophthalmol, 2017, 53: 81-84).

Entities:  

Keywords:  Blindness; Glaucoma; Health Education; Vision, low

Mesh:

Year:  2017        PMID: 28260356     DOI: 10.3760/cma.j.issn.0412-4081.2017.02.001

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  2 in total

1.  Vision-related quality of life in patients with glaucoma: the role of illness perceptions.

Authors:  Qiqi Zhang; Wenzhe Zhou; Di Song; Yanqian Xie; Hao Lin; Youping Liang; Yanhan Ren; Yuanbo Liang; Yanyan Chen
Journal:  Health Qual Life Outcomes       Date:  2022-05-12       Impact factor: 3.077

2.  Causes and Three-year Incidence of Irreversible Visual Impairment in Jing-An District, Shanghai, China from 2010-2015.

Authors:  Fei Xia; Liangcheng Wu; Chenghai Weng; Xingtao Zhou
Journal:  BMC Ophthalmol       Date:  2017-11-28       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.